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uncertain. Furthermore, there is no evidence that triglycerides or free fatty acids directly
impair vascular function as opposed to reflex or hormonal changes induced following
systemic exposure.
Methods: We tested the hypothesis that local HTG impairs resistance vessel endothelial
function, by examining whether forearm blood flow (FBF) responses to intra-arterial ace-
tylcholine (Ach), bradykinin (BK), and nitroprusside were altered by coinfusion of
intralipid (IL 200 mg/min) for 90 min in 10 healthy adults; age 39±4, 7M.
Results: IL increased plasma triglycerides from 80±20 to 433±62 and free fatty acids
from 0.5±0.1 to 1.9±0.2 (p=0.0003 for both). Forearm vasodilatation to Ach (p=0.83), BK
(p=0.73), and nitroprusside (p=0.34) were not reduced by HTG (figure).
Conclusion: Local HTG sustained for >90 min does not impair resistance vessel endot-
helial function. These results suggest that resistance vessels are less susceptible to the
deleterious effects of triglycerides than conduit vessels. Alternatively, the vascular effects
of systemic HTG may be mediated indirectly, perhaps via hormonal or reflex mecha-
nisms.
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1160-165 Angiotensin II Receptor 1 Blocker Improves Not Only 
Hypertension but Also Ventricular Arrhythmogenicity
Chikashi Suga, Kazuo Matsumoto, Ritsushi Kato, Toshimasa Tosaka, Atsushi Sakamoto, 
Madoka Nozawa, Yurika Hotta, Osami Komoto, Shigeyuki Nishimura, Hiroshi Suga, 
Saitama Medical School, Saitama, Japan, Suga Clinic, Saitama, Japan
Background: Angiotensin II receptor 1 blocker (ARB) has been proven to improve car-
diovascular mortality and morbidity. However, the influence of ARB on fatal arrhythmia
remained unknown. The purpose of this study was to evaluate if ARB has any beneficial
effect on ventricular arrhythmogenicity, and also if the effect is associated with the
decrease of blood pressure.
Methods: This study consists of 69 patients (30 males, mean age 63.8±10 years) with
hypertension in whom valsartan was administrated from February 2001 to May 2002. We
assessed mean blood pressure (MBP), RV5+SV1 on ECG, QT dispersion (QTD) and QTc
dispersion (QTcD) before and 10 months later of introduction of valsartan administration.
We also assessed correlation between the difference of QTD or QTcD before and 10
month later of the valsartan administration and the difference of MBP or RV5+SV1 before
and 10 month later of the valsartan administration.
Results: MBP (119.9±12.1mmHg vs. 101.9±10.6mmHg, p<0.0001), QTD
(60.3±16.8msec vs. 47±11.3msec, p<0.0001) and QTcD (62.6±17.1msec vs.
49.3±12.6msec, p<0.0001) except RV5+SV1 (2.62±1.09mV vs. 2.53±0.98mV, NS) signifi-
cantly decreased through the study period. There was no significant correlation between
the difference of QTD or QTcD before and 10 month later of the valsartan administration
and the difference of MBP or RV5+SV1 before and 10 month later of the valsartan admin-
istration.
Conclusion: QTD and QTcD decreased after valsartan administration. The decrease of
QTD and QTcD did not correlate with the change of blood pressure or RV5+SV1. Thus, it
is suggested that valsartan might have beneficial effect on ventricular arrhythmogenicity
that could not be explained by the improvement of hypertension or left ventricular hyper-
trophy.
1160-166 C-Type Natriuretic Peptide Improves Left Ventricular 
Performance at Rest and During Exercise After Heart 
Failure
Hiroshi Hasegawa, Atsushi Morimoto, Heng-Jie Cheng, William C. Little, Che-Ping 
Cheng, Wake Forest University School of Medicine, Winston-Salem, NC
Background. The diastolic dysfunction present at rest is exacerbated during exercise
(Ex) in heart failure (CHF). C-type natriuretic peptide (CNP), the third member of the
natriuretic peptide family with vasodilating, natriuretic, and lusitropic actions, may prevent
this abnormal Ex response after CHF.
Methods. We assessed the effects of CNP on left ventricular (LV) systolic and diastolic
performance at rest and during submaximum Ex (3.5-5.5 mph for 5-8 min) in 8 chroni-
cally instrumented dogs with pacing-induced CHF. Since CNP mediated its biological
actions via cGMP, we also measured plasma cGMP levels in response to CNP infusion at
rest before and after CHF.
Results. CNP (2 µg/kg plus 0.4 µg/kg/min, iv, 20 min) caused a similar increase in cGMP
levels before (7.7±4.4 to 29.4±5.7 pmol/ml) and after CHF (27.7±4.4 to 69.4±5.7 pmol/
ml). At rest, treatment with CNP produced reductions in LV end-systolic pressure (PES,
92±10.8 vs 102±12.1 mmHg), arterial elastance (EA, 8.6±1.2 vs 12.2±1.4 mmHg/ml) and
end-diastolic pressure (PED, 38.4±4 vs 43.2±6 mmHg) (p<0.05). The peak mitral flow
(dV/dtmax, 198±59 vs 164±38 ml/sec) was also increased due to decreases in minimum
LVP (LVPmin, 18.6±6.7 vs 23.3±6.3 mmHg) and the time constant of LV relaxation (τ,
41±7 vs 46±7 msec) (p<0.05). In addition, the slope of LV end-systolic pressure-volume
relations (EES) produced by caval occlusion was also increased (5.4±0.6 vs 4.1±0.5
mmHg/ml). The LV-arterial (A) coupling (C), quantified as EES/EA, was improved
(0.68±0.20 vs 0.49±0.18) (p<0.05). The beneficial effects persisted during Ex after CHF.
At matched levels of Ex, treatment with CNP tolerated Ex-induced increases in PES (∆P=
3.3±0.2 vs 7.3±0.4 mmHg), mean LAP (∆P= -3.2±2.6 vs 3.1±2.7 mmHg), and LVPmin
(∆P= -3.4±1.2 vs 1.3±1.0 mmHg) (p<0.05). With CNP, τ was much shortened (∆= -
0.6±4.0 vs 2.9±3.7 ms), and peak mitral flow
 
was further augmented (∆dV/dtmax, 71±23
vs 41±12 ml/sec) (p<0.05).
Conclusion. After CHF, the generation of cGMP in response to CNP is not blunted. CNP
produces arterial vasodilatation and augments LV relaxation, diastolic filling and LV arte-
rial coupling, thus improving LV performance, both at rest and during Ex after CHF.
1160-167 Defining the Acute Cardiorenal Response to High Dose 
Nesiritide in Severe Experimental Congestive Heart 
Failure
John A. Schirger, Alessandro Cataliotti, Horng H. Chen, Guido Boerrigter, Lisa C. 
Costello-Boerrigter, Fernando L. Martin, Gail J. Harty, John C. Burnett, Jr., Mayo Clinic, 
Rochester, MN
Background: Previous human studies report improved cardiac filling pressures and glo-
bal clinical status in acute decompensated congestive heart failure (CHF) using human
brain natriuretic peptide (BNP)/Nesiritide. Severe CHF however may be associated with
emergence of reduced sensitivity to BNP due to receptor down-regulation, enhanced
degradation or reduced renal perfusion pressure. We investigated the effects of clinical
and high dose IV Nesiritide on systemic hemodynamics, renal function, and sodium
excretion in severe canine CHF, hypothesizing that supraclinical doses further reduce
cardiac filling pressures and enhance sodium excretion without marked hypotension.
Methods: We used an established model of pacing induced (240 bpm, 10 days) severe
canine (n=7) CHF characterized by decreased cardiac output, increased cardiac filling
pressures, sodium retention and neurohumoral activation. After a baseline clearance IV
Nesiritide was infused with a lead in period followed by 30 minute clearances at doses of
100 (approximating doses in clinical trials) and 1000 ng/kg/min (10 fold greater than clini-
cal trials).
Results: Clinical dosing decreased pulmonary capillary wedge pressure (PCWP) (23±1
vs 18±1 mmHg, p<0.05), pulmonary artery pressure (PAP) (31±3 vs 27±2 mmHg,
p<0.05), and mean arterial pressure (MAP) (105±4 vs 87±4 mmHg, p<0.05), and tended
to increase cardiac output (CO) (1.43±0.21 vs 1.91±0.39 L/min) vs baseline. High dose
IV Nesiritide further deceased PCWP (17+2 mmHg, p<0.05) and PAP (25±1 mmHg,
p<0.05), without further decreasing MAP, and tended to further increase CO. Importantly,
glomerular filtration rate tended to increase compared to baseline (26±5 L/min) with both
clinical (41±10 L/min) and high (48±15 L/min) doses of IV Nesiritide. Urinary sodium
excretion tended to increase at clinical dosing (7±4 µEq/min)and significantly increased
(12±6 µEq/min, p<0.05) with high dose IV Nesiritide vs baseline (2± 0.4 µEq/min) in the
absence of further decreases in MAP.
Conclusion: These studies in experimental CHF suggest it may be possible to increase
the dosing of IV Nesiritide, thus warranting carefully designed future human investiga-
tions in severe CHF.
1160-168 The Estrogen-Induced Alterations in Arterial Stiffness 
are Independent of the Non-Dipping Status but 
Attenuated by Progesterone in Hypertensive 
Postmenopausal Women
C. Tsioufis, K. Tzioumis, A. Hatziyianni, K. Dimitriadis, E. Taxiarchou, D. Hatzis, C. 
Stefanadis, I. Kallikazaros, P. Toutouzas, Athens Univeristy, Athens, Greece, 
Hippokration Hospital, Athens, Greece
Background: Large artery stiffness and attenuated nocturnal blood pressure (BP) fall are
associated with unfavorable cardiovascular outcome, in essential hypertension. We
assessed the hypothesis that the addition of progesterone and the absence of normal cir-
cadian BP variation may modify the beneficial effects of hormonal replacement therapy
(HRT) on large artery distensibility in hypertensive postmenopausal women.
Methods: For this purpose, we studied aortic stiffness in 56 postmenopausal women
(aged 52 years, 3.4 years after menopause) with untreated, mild essential hypertension
randomized to conjugated estrogen alone (n=20), estrogen plus medroxyprogesterone
(n=20) or placebo (n=16). Aortic elasticity was evaluated, non-invasively, on the basis of
pulse wave velocity (PWV) measurements at baseline and at 12 weeks after treatment.
At baseline, women receiving conjugated estrogen alone, underwent 24h ambulatory BP
monitoring and were classified to non-dippers (defined by a reduction in the night mean
systolic and diastolic BP <10% from day values) (n=7) and dippers (the remaining sub-
jects) (n=13).
Results: In the entire study population office BP was 146/93 mmHg and left ventricular
mass index was 104±26 gr/m2. The patients’ groups were matched for age, time since
menopause, smoking status, office blood pressure and PWV values at baseline. At 12
weeks of treatment, in women receiving estrogen alone, aortic PWV was significantly
reduced (6.31 vs 6.09 m/sec, p<0.005), while in those receiving combined HRT or pla-
cebo, PWV did not change (6.32 vs 6.28 and 6.33 vs 6.30 m/sec, respectively, p=NS for
both cases). Treatment with conjugated estrogen induced a significant reduction in aortic
PWV in both groups of dippers and non-dippers, after 12 weeks. Furthermore, the
degree of reduction in PWV did not differ in dippers (by 0.27 m/sec) and non-dippers (by
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0.25 m/sec) (p=NS).
Conclusion: Long-term combined HRT has no favorable effects on large artery compli-
ance in hypertensive postmenopausal women. In the same population, abnormal circa-
dian BP variability does not attenuate the estrogen-induced alterations in arterial
elasticity.
1160-169 Short Term Estrogen Replacement Therapy Improves 
Cardiovascular Autonomic Response in 
Postmenopausal Women: A Double-Blind Randomized 
Placebo Controlled Trial
Juan C. Guzman, Ronald G. Garcia, Juan P. Casas, Luis A. Diaz, Patricio Lopez-
Jaramillo, Carlos A. Morillo, Carlos A. Morillo, Fundacion Cardiovascular de Colombia, 
Floridablanca, Colombia, Universidad Autonoma de Bucaramanga, Bucaramanga, 
Colombia
BACKGROUND: Estrogen deficit may lead to cardiac autonomic function imbalance in
the postmenopausal women that may potentially increase cardiovascular risk. The physi-
ological mechanism by which estrogen replacement therapy (ERT) regulates the auto-
nomic nervous system in postmenopausal women remains unclear.
METHODS: Thirty nine patients aged 45-65 years with a previous total hysterectomy and
amenorrhea for 1 year prior to the surgery were enrolled in this prospective, randomized
double-blind, placebo-controlled trial. Women with obesity, cardiovascular, neurological
or metabolic disease were excluded. Conjugated estrogens were administered at a dose
of 0.625 mg daily during 12 weeks in 19 patients (52.6± 7.1 years), and matched placebo
in 20 women (53.8± 5.4 years). Cardiopulmonary and arterial baroreceptor response
was determined after 3 months of treatment in both groups. Arterial baroreflex sensitivity
(BRS) was determined after the intravenous bolus administration of vasoactive sub-
stances (phenylephrine 150 mcg, sodium nitroprussiate,100 mcg). Cardiopulmonary
baroreflex response(CBR) was calculated using venous occlusion plethysmography by
determining forearm blood flow changes (FBF) and peripheral vascular resistance (PVR)
to –10mmHg lower-body negative pressure (LBNP). All measurements were performed
between 8am-12m. All signals were analyzed with the winCPRS software (Absolutely
Aliens, Finland).
RESULTS: A significant increase in BRS was found after 3 months of ERT compared
with placebo; Phenylephrin; 9.28 ±3.72 vs 15.93±10.22, p=0.09 and Nitroprussiate;
6.7±2.73 vs. 12.68±8.40, p<0.01. During LBNP a higher FBF (1.10±0.39 vs.
0.81±0.15,p<0.05) was associated with lower PVR (97.7±32.5 vs. 129.4±43.5, p<0.05) in
the group receiving ERT compared to the placebo group.
CONCLUSIONS: Short term ERT (3 months) may modulate cardiovascular autonomic
responses leading to reduced sympathetic activity (PVR) and improving cardiovagal
response by increasing arterial baroreflex sensitivity in postmenopausal women. (Col-
ciencias Grant: 6566-04-11788)
1160-170 Irbesartan Significantly Reduces C-Reactive Protein 
After One Month of Therapy in Unstable Angina
Mariaelena Lombardi, Luigi M. Biasucci, Maddalena Piro, Giovanna Di Giannuario, Giulia 
Aguzzi, Sonia Iacovella, Giovanna Liuzzo, Filippo Crea, Institution of Cardiology. Catholic 
University, Rome, Italy
Background: A growing body of evidence supports the patophysiological role of renin-
angiotensin-system (RAS) in the athero-trombotic process, in cardiac remodelling and in
apoptosis. Angiotensin II (AgII) blockade seems to be able to reduce the progression of
atherosclerotic lesion, through an anti-inflammatory mechanism. A reduction of coronary
events has also been observed in trials with these classes of drugs. Therefore we evalu-
ated whether Irbersartan (a selective AgII blocking agent) may modulate the inflamma-
tory response in unstable angina (UA). Methods: We studied 25 UA (Braunwald’s class
IIIB) patients (pts) without hypertension, diabetes, heart failure. Patients were treated
with full conventional anti-ischemic therapy (i.v. nitrates, aspirin, clopidogrel, β -blockade,
statins, low molecular weight-heparin) except Angiotensin Converting Enzyme-inhibitors
and/or AgII inhibitors. Pts were divided into two groups of treatment: group 1 receiving
Irbesartan (300 mg/die) on the top of conventional treatment and group 2 receiving con-
ventional treatment and placebo. Patients were discharged with aspirin, clopidigrel, β -
blocking agents plus Irbesartan (group 1) or placebo (group 2). In all patients we mea-
sured High Sensitivity-CRP levels (Dade-Behring) at Coronary Care Unit entry and after
1 and 3 months of follow up. Results: At entry, CRP levels (median and range) were sim-
ilar in group 1 and group 2 (3.1; 0.7-17.7 and 2.5; 1.1-21.9 mg/L). In group 1, CRP signif-
icantly decreased after 1 and 3 months of follow up, being respectively 1.2 mg/L; 0.16-
10.07 and 0.86; 0.58-4.17 mg/L (P=0.038 versus entry), whereas no changes were
observed in group 2 (2.25; 0.99-4.09 and 1.57;0.22-5.75 mg/L at 1 and 3 months respec-
tively). Conclusions: Our data demonstrate that Irbesartan has an in vivo antinflamma-
tory effects as shown by reduction of CRP levels in patients receiving full medical
therapy, including statins,and after only one month of treatment. Our data suggest a role
for AgII inhibitors in plaque stabilization and may help to explain the reduction of coronary
events in patients treated with AgII Inhibitors.
1160-197 Decreased Serum Ghrelin and Insulin-Like Growth 
Factor-I Levels Associated With Insulin Resistance in 
Patients With Acute Heart Failure: Analysis by Steady-
State Plasma Glucose Method
Satoshi Yasuda, Shunichi Miyazaki, Hiroshi Hosoda, Noritoshi Nagaya, Munetake 
Kanda, Masaaki Hasegawa, Yutaka Harano, Yoichi Goto, Hiroshi Nonogi, Kenji Kangawa, 
National Cardiovascular Center, Osaka, Japan
Background: Ghrelin, a novel and key peptide of energy homeostasis, is associated with
the growth hormone – insulin-like growth factor (IGF)-I axis. Previous studies demon-
strated that IGF-I plays a role in pathogenesis of heart failure (HF), in which metabolic
abnormalities such as insulin resistance may be induced. Thus, the present study was
designed to investigate the role of insulin resistance and its relation with ghrelin and/or
IGF-I in patients with HF.
Methods: We studied 14 patients; seven healthy control subjects (M/F=4/3, age: 62±4
[mean±SD] years), and seven patients with acute HF (NYHA class IV), without diabetes
mellitus or obesity (M/F=5/2, age: 63±11 years). Insulin sensitivity was assessed at 1
week and 3-6 months following acute HF by the steady-state plasma glucose (SSPG)
method using a somatostatin derivative, octreotide acetate. Blood samples were col-
lected to measure the levels of ghrelin and IGF-I. Serum ghrelin level was measured by
newly developed enzyme immunoassay system.
Results: In comparison with the control (76±8 mg/dl), the SSPG level in HF patients was
significantly increased at 1 week (118±30 mg/dl, P<0.01), indicating insulin resistance.
However, at 3-6 months following acute HF, the SSPG level was restored to the control
level (80±21 mg/dl) with the significant increase in serum ghrelin (from 12±6 to 29±28
fmol/mL, P<0.05) and IGF-I levels (from 106±17 to 122±18 ng/mL, P<0.05). In patients
with HF, ghrelin level correlated inversely with insulin resistance (R=-0.625, P<0.01) and
positively with IGF-I level (R=0.675, P<0.01).
Conclusions: In patients with acute HF, insulin resistance is induced in association with
decreased ghrelin and IGF-I levels. The present findings suggest a potential interaction
between the ghrelin-IGF-I system and glucose metabolism by insulin, which may contrib-
ute to pathophysiology of HF.
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1161-171 Blood Pressure Response to Strength Training Is 
Influenced by AGT (-20) Genotype in the Elderly
Anish Meerasahib, Ben Hurley, G. Martel, Steve Roth, University of Maryland,College 
Park, College Park, MD
Background: Several linkage and association studies support the role of the Angiotensi-
nogen (AGT) gene in the development of essential hypertension. The C/A polymorphism
at -20 position has been shown to modify the expression of AGT, which can elevate BP
by raising blood levels of AGT. The purpose of the investigation was to study the relation-
ship of AGT (-20) genotype with resting BP response to Strength Training (ST) in middle-
aged to older adults.
Methods: Fifty-five sedentary, healthy men and women who were homozygous for ade-
nine allele (A/A, n=37, 21 men & 16 women) or heterozygous (A/C, n=18, 11 men & 7
women) at AGT gene locus were enrolled in the study. All subjects went through three to
six months of ST done 3 days per week using Keiser air-powered variable resistance
exercise machines, each session lasting for approximately 45 minutes. One-repetition
maximum (1RM) strength, Body Fat (%) and Fat Free Mass were measured before and
after the ST program. Resting Systolic and Diastolic BP were measured on six separate
occasions before and after ST for each subject. AGT genotyping was performed from
each subject's genomic DNA.
Results: Significant training induced reductions were noticed in systolic BPs of female
subjects, which dropped from 123.4 ± 11.3 mm Hg to 120.1 ± 11.4 mm Hg (P<0.05). The
male subjects dropped their diastolic BPs from 77.2 ± 7.9 mm Hg to 75.0 ± 7.1mm Hg
(P<0.05). When analyzed using ANCOVA, accounting for the genotype and the differ-
ences in pre-systolic BP between the two genotypes, the change in systolic BP was sig-
nificantly greater in AA genotype than AC/CC genotype. Systolic BP in AA genotype
dropped from 128.2 ± 2.0 mm Hg to 123.8 ± 1.6 mm Hg (P<0.05), while AC/CC genotype
dropped their systolic BP from 121.0 ± 2.5 mm Hg to 119.8 ± 3.2 mm Hg (P<0.05). When
controlled for the differences in pre-diastolic BP between the two genotypes, the change
in diastolic BP was not significantly different between the two genotypes.
Conclusion: AGT (-20) genotype influences resting blood pressure response to strength
training such that training reduces systolic BP in homozygotes to a more degree than that
in heterozygotes.
1161-172 Upregulation of Akt and Endothelial Nitric Oxide 
Synthase Induces Vascular Smooth Muscle Cell 
Differentiation in Hypertension In Vivo
Shinji Kawahara, Seiji Umemoto, Masakazu Tanaka, Kyoko Umeji, Ryo Hashimoto, 
Susumu Matsuda, Masunori Matsuzaki, Yamaguchi University Graduate School of 
Medicine, Ube,Yamaguchi, Japan
Background Recent studies have shown that angiotensin II type 1 (AT1) receptor-medi-
ated Akt activation induced vascular smooth muscle cell (VSMC) dedifferentiation in vitro.
However, the critical signal transductions affecting the VSMC phenotype remain unclear
in vivo. We examined which signal transduction acting through the AT1 receptor could
regulate the VSMC phenotype in SHRSP in vivo. Methods and Results- Male stroke-
prone hypertensive rats (SHRSP) were randomized and treated for 6 weeks with a vehi-
cle (n=20), an AT1 receptor antagonist (E4177; 30 mg/kg/day, n=20), or an angiotensin-
converting enzyme (ACE) inhibitor (cilazapril; 10 mg/kg/day, n=20). Protein expressions
were analyzed by immunoblots, and NAD(P)H oxidase activity measured by lumines-
cence assay. Both drugs showed equipotent effects on blood pressure, aortic morphol-
ogy, collagen deposition, p38 mitogen-activated protein kinase and p42/44 extracellular
signal-regulated kinase expression in the aorta (P<0.05 vs. the vehicle group, respec-
